Belantamab mafodotin remains in development, with its maker, GlaxoSmithKline, aiming for an upfront MM indication.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/blenrep-returns-adc-combo-approved-r-r-mm-2025a1000t27?src=rss
Author :
Publish date : 2025-10-24 16:01:00
Copyright for syndicated content belongs to the linked Source.